b.next is building the technology and infrastructure that make it possible to use synthetic cells to solve the world's hardest problems. Since launching in June 2023, b.next has catalyzed a global research community building synthetic cells together. We built and maintain Nucleus, an open platform for building synthetic cells (https://nucleus.engineering). We operate a manufacturing plant for synthetic cells. We pursue R&D programs that bring synthetic cells from the lab into the world.
| Website | https://bnext.bio |
| Employees | 13 (11 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
| Keywords | Biotech, Synthetic Biology, Biotechnology Innovation, Bioengineering, Biotechnology, Engineering Biology, Genetic Engineering, Biomanufacturing, Biotechnology Research, Biological Engineering, Cellular Engineering, Molecular Engineering, Biomedical Engineering, Genome Engineering, Protein Engineering, Metabolic Engineering, Tissue Engineering, Bioprocess Development |
| Competitors | CARB-X, Zymergen, Inc., Zymeworks Inc., Moderna Therapeutics, Amgen, AstraZeneca, Illumina, Biogen, Novartis, Regeneron +39 more (view full list) |
Looking for a particular b.next employee's phone or email?
Akshay Maheshwari is the Co-Founder and CEO of b.next.
11 people are employed at b.next.